Clostridium difficile--more difficult than ever.
Kelly
Ciarán P
CP
Gastroenterology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.
LaMont
J Thomas
JT
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000907:Antibodies, Bacterial / Q000097:blood; D001427:Bacterial Toxins / Q000378:metabolism; D016360:Clostridioides difficile / Q000276:immunology / Q000472:pathogenicity* / Q000502:physiology; D003015:Clostridium Infections / Q000453:epidemiology / Q000628:therapy / Q000821:virology; D003428:Cross Infection / Q000453:epidemiology / Q000382:microbiology; D004196:Disease Outbreaks; D004761:Enterocolitis, Pseudomembranous; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007167:Immunotherapy; D015994:Incidence; D019936:Probiotics / Q000627:therapeutic use; D055502:Secondary Prevention; D014481:United States / Q000453:epidemiology
D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D001427:Bacterial Toxins; D007074:Immunoglobulin G